TY - JOUR
T1 - Not enough known about fenofibrate's kidney effects in people with Type 2 diabetes
AU - FIELD Trial Study Group
AU - Jenkins, Alicia J.
AU - O'Connell, Rachel L.
AU - Januszewski, Andrzej S.
AU - Webster, Angela C.
AU - M.E. Davis, Timothy
AU - Jardine, Meg J.
AU - Scott, Russell S.
AU - Taskinen, Marja Riitta
AU - Keech, Anthony C.
N1 - Publisher Copyright:
© 2024 The Author(s)
PY - 2024/4
Y1 - 2024/4
N2 - Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.
AB - Globally ≈10% of adults have diabetes, with 80% in disadvantaged regions, hence low-cost renoprotective agents are desirable. Fenofibrate demonstrated microvascular benefits in several cardiovascular end-point diabetes trials, but knowledge of effects in late-stage kidney disease is limited. We report new FIELD substudy data and call for further kidney outcomes data.
UR - http://www.scopus.com/inward/record.url?scp=85188014230&partnerID=8YFLogxK
U2 - 10.1016/j.diabres.2024.111612
DO - 10.1016/j.diabres.2024.111612
M3 - Article
C2 - 38479447
AN - SCOPUS:85188014230
SN - 0168-8227
VL - 210
JO - Diabetes Research and Clinical Practice
JF - Diabetes Research and Clinical Practice
M1 - 111612
ER -